The biotechnology firm Axol Bioscience raised $2.8m, with plans to expand its Edinburgh operations.
The Roslin Foundation, the company’s original investor, also took part in the investment, which was headed by US life sciences expert BroadOak Capital Partners.
Induced pluripotent stem cell (iPSC) methods for drug discovery and disease research are supplied by Axol.
Axol’s next phase of growth will be accelerated by the funding, which will help the company expand its commercial presence and operations in the United States.
In response to growing customer demand for more human-relevant in vitro disease models worldwide, it will also make it possible to build improved models for brain, ophthalmology, and cardiovascular diseases as well as scale up cell manufacturing at its Roslin Innovation Center headquarters.
Axol Bioscience creates and provides pharmaceutical, biotech, CROs, and academic institutions throughout the world with functioning iPSC-derived cells, reagents, and specialized services.
Liam Taylor, CEO of Axol Bioscience, said:
“We’re proud to partner with BroadOak, a global leader in life sciences investing.
Their expertise and support, alongside our long-term partner Roslin Foundation, reflects confidence in our long-term vision, team, products, and technology as we scale operations and expand internationally.”
Oliver Richardson, CFO, added:
“Following Axol’s 45% revenue growth in 2025 and 36% in 2024, this funding allows us to strengthen our US operations and expand manufacturing capacity at our Edinburgh site, ensuring we can continue to meet increasing global demand.”
Daniel Friedman, managing director at BroadOak Capital Partners, said:
“Axol is a leader in their space and is well positioned as global regulators actively usher in the adoption of cell-based models.
We are excited to be partnering with Liam, Oli, and the entire Axol team to support their next phase of growth.”
Who led Axol Bioscience’s funding round and who participated?
BroadOak Capital mates, a US life lores investor, led Axol Bioscience’s$ 2.8 million(£ 2.1 million) seed backing round on January 13, 2026.
The Roslin Foundation, Axol’s launching backer and driver of the Edinburgh manufacturing point, also shared in the round. No other investors were named in public adverts, though previous rises involved Calculus Capital and Par Equity supporting the 2024 Censo Biotechnologies junction.
BroadOak’s Managing Director Daniel Friedman stressed Axol’s leadership in iPSC- deduced cell models for neuroscience, ophthalmology, and cardiovascular exploration, situating the establishment amid nonsupervisory shifts toward mortal-applicable druthers to animal testing. Roslin’s uninterrupted support underscores Edinburgh’s stem cell ecosystem solidarity with Cambridge R&D.
